Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

UPDATE: Tissue Regenix produces impressive results in leg ulcer trial

Shares in Tissue Regenix were lifted more than 12% today as its replacement skin continued to generate impressive results in a UK trial to treat chronic leg ulcers.
UPDATE: Tissue Regenix produces impressive results in leg ulcer trial

---Adds share price and quotes from managing director---

Shares in Tissue Regenix (LON:TRX) were lifted more than 12% today as its replacement skin continued to generate impressive results in a UK trial to treat chronic leg ulcers.

All 20 patients treated with the company's dCELL Dermis saw a significant reduction in their wounds while nine were completely healed, it said.

The firm's dCELL Dermis is human skin that has been treated with its dCELLprocess - a patented technology that involves taking human or animal tissue and “washing” it so that it can be used again to replace worn out or diseased body parts without the risk of rejection.

The ongoing trial is being carried out in conjunction with the NHS Blood and Transplant division and is focused on people who have suffered with chronic ulcers for more than four years.

As well as the nine patients being healed, the surface area of all of the patient’s ulcers had halved in size, with volume also reduced significantly. The results were after six weeks.

The study also showed that the new skin could be applied in 30- 40 minutes without hospital admission in out-patient clinics and potentially GP surgeries.

Dr Ardeshir Bayat, the trial's principal investigator at the University Hospital of South Manchester said: "Chronic wounds of the lower leg are a clinical challenge and their on-going treatment costs the NHS in excess of £400m per annum. 

"Therefore a novel solution that can both reduce these costs and simultaneously offer a more effective treatment strategy has been long overdue."

Antony Odell, Tissue Regenix’s managing director, added: "People who suffer with chronic leg ulcers often do so for many years. 

"Traditional treatments using compression bandages are not effective in many cases and require regular hospital visits and the associated disruption to their daily lives."

He told Proactive Investors the firm was "very encouraged" by these results.

"It's another demonstration of the utility of the dCELL technology in another indication," he said.

The next step, he said, would be to carry out a larger clinical study, but also to begin to look at commercialising CELL Dermis.

Tissue is keen to see it launched outside the UK and has begun talks in the US about a clinical trial there, he said.

"We are quietly confident that we'll get some people to be interested enough to pick it up and want to do this clinical work."

Earlier, Odell told investors that the company expects to publish the results of a pre-clinical knee cartilage replacement trial before the end of the year, while a number of different products including the ligament and cardiac patch are due to enter preclinical studies.

Tissue Regenix has also been selected as one of only twenty UK healthcare companies to attend the Future Healthcare Mission to showcase the best in UK medical and healthcare science and technology to US investors and business partners, he said. 

“We believe Tissue Regenix is an excellent example of a British company with world-beating technology, which is based on research conducted in UK universities and pioneered through patient treatment in the NHS."

Tissue had net cash at the end of July of £26.1 mln. The company raised £25m through a share placing in December.

Losses in the half year rose to £1.87 mln from £1.34 mln reflecting the heavy product development currently underway, it said.

Shares rose today 12.22%, to stand at 12.50 pence.

View full TRX profile View Profile

Tissue Regenix Group PLC Timeline

Related Articles

Cellmid's Maria Halasz with investors at Proactive's CEO Sessions
October 06 2017
Maria Halasz discussed rapidly growing hair care sales at Proactive's CEO Sessions.
m&a icon of bug fish swallowing big fish
December 04 2017
It is paying an initial US$13mln for Vamousse, which it is acquiring from TyraTech, the AIM-listed developer of the range. This will be followed by a deferred pay-out of as much as US$4.5mln based on sales targets
Clinical Trial
August 04 2017
The study, codenamed INTEREST, should be wrapped up in the fourth-quarter

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use